Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells (Zhejiang University)
- Development stage
- Unknown
- Lead developer
- Children's Hospital, Zhejiang University School of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-CD19 CAR-T cells (Zhejiang University) is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed by The Children's Hospital of Zhejiang University School of Medicine for the treatment of refractory systemic sclerosis. The therapy involves harvesting a patient's peripheral blood mononuclear cells, which are then transduced with a lentiviral vector to express a CAR targeting the CD19 antigen found on B cells. Following lymphodepletion with fludarabine and cyclophosphamide, the modified T cells are re-infused into the patient. The mechanism of action relies on the targeted elimination of CD19+ B cells, which play a critical role in the autoimmune pathogenesis of systemic sclerosis. It is currently being evaluated in a Phase 1 investigator-initiated clinical trial (NCT05085444) for both adult and childhood-onset refractory systemic sclerosis.
- Other names
- CD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsanti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsautologous CD19-targeted CAR-T cells
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-T cells (Zhejiang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells (Zhejiang University).